SEC Stock Data Quick Answer Antero Midstream Corp reported Total Revenue of $1.19 billion for fiscal year 2025. Antero Midstream Corp Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $1.19B +7.4% 2024 $1.11B +6.2% 2023 $1.04B +13.2% 2022 $919.99M +2.4% 2021 $898.20M -0.3% 2020 $900.72M +13.6% 2019 $792.59M +454.6% 2018 $142.91M +105.0% 2017 $69.72M … Read more
Quick Answer Antero Midstream Corp reported Total Revenue of $1.19 billion for fiscal year 2025. Antero Midstream Corp — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $1.19B+7.4% $1.11B+6.2% $1.04B+13.2% $919.99M+2.4% $898.20M-0.3% $900.72M+13.6% Net Income — — — — — — Diluted EPS $0.86+3.6% $0.83+7.8% $0.77+13.2% $0.68-1.4% $0.69+365.4% -$0.26+67.5% Total … Read more
Quick Answer Alzamend Neuro, Inc. reported Shares Outstanding of 778.7 thousand shares for fiscal year 2025. Alzamend Neuro, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 778,733 +918.7% 2024 76,444 -88.2% 2023 646,267 -99.3% 2022 95.48M +41.6% 2021 67.43M +4.1% 2020 64.76M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding … Read more
Quick Answer Alzamend Neuro, Inc. reported Operating Income of -$4.50 million for fiscal year 2025. Alzamend Neuro, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$4.50M +54.7% 2024 -$9.94M +33.2% 2023 -$14.87M -20.7% 2022 -$12.32M -148.8% 2021 -$4.95M -11.9% 2020 -$4.42M — Quarterly Operating Income Quarter Ending Operating Income YoY … Read more
Quick Answer Alzamend Neuro, Inc. reported R&D Expense of $1.41 million for fiscal year 2025. Alzamend Neuro, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $1.41M -78.1% 2024 $6.46M -13.3% 2023 $7.45M +43.2% 2022 $5.20M +296.8% 2021 $1.31M +22.6% 2020 $1.07M — Quarterly R&D Expense Quarter Ending R&D Expense YoY … Read more
Quick Answer Alzamend Neuro, Inc. reported Stockholders Equity of $3.97 million for fiscal year 2025. Alzamend Neuro, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $3.97M +253.0% 2024 -$2.59M -185.2% 2023 $3.05M -77.2% 2022 $13.35M +563.3% 2021 $2.01M +145.0% 2020 $821.7K +159.3% 2019 $316.9K — Quarterly Stockholders Equity Quarter Ending … Read more
Quick Answer Alzamend Neuro, Inc. reported Cash and Equivalents of $3.95 million for fiscal year 2025. Alzamend Neuro, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $3.95M +950.0% 2024 $376.0K -92.7% 2023 $5.14M -63.4% 2022 $14.06M +629.0% 2021 $1.93M +2036.9% 2020 $90.3K +111.9% 2019 $42.6K — Quarterly Cash … Read more
Quick Answer Alzamend Neuro, Inc. reported Total Assets of $4.60 million for fiscal year 2025. Alzamend Neuro, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $4.60M +628.8% 2024 $631.6K -89.3% 2023 $5.92M -59.2% 2022 $14.52M +398.4% 2021 $2.91M +60.6% 2020 $1.81M — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more
Quick Answer Alzamend Neuro, Inc. reported Diluted EPS of $11.32 per share (loss) for fiscal year 2025. Alzamend Neuro, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$11.32 +91.4% 2024 -$132.33 -478.1% 2023 -$22.89 -16250.0% 2022 -$0.14 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ October 31, 2025 … Read more
Quick Answer Alzamend Neuro, Inc. reported Net Income of -$4.51 million for fiscal year 2025. Alzamend Neuro, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$4.51M +54.6% 2024 -$9.95M +33.1% 2023 -$14.88M -20.4% 2022 -$12.36M -145.0% 2021 -$5.05M -14.4% 2020 -$4.41M — Quarterly Net Income Quarter Ending Net Income YoY … Read more